Cathrine L. Lorentzen

Herlev, Denmark

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

Tumor Infiltrating Lymphocyte Therapy Combined With PD-1/LAG-3 Inhibition in Patients With Recurrent Platinum-Resistant Ovarian Cancer.

Tumor Infiltrating Lymphocyte Therapy Combined With PD-1/LAG-3 Inhibition in Patients With Recurrent Platinum-Resistant Ovarian Cancer.

Journal: International journal of cancer

Published: September 16, 2025

Five-year clinical outcome and immune biomarkers of durable response from the MM1636 trial on IDO/PD-L1 vaccination and PD-1 blockade in first line metastatic melanoma.

Five-year clinical outcome and immune biomarkers of durable response from the MM1636 trial on IDO/PD-L1 vaccination and PD-1 blockade in first line metastatic melanoma.

Journal: Nature communications

Published: June 19, 2025

Safety and efficacy of combined treatment with tumor-infiltrating lymphocytes and oncolytic adenovirus TILT-123 in metastatic melanoma.

Safety and efficacy of combined treatment with tumor-infiltrating lymphocytes and oncolytic adenovirus TILT-123 in metastatic melanoma.

Journal: Cell reports. Medicine

Published: August 29, 2024

Long-term follow-up of anti-PD-1 naïve patients with metastatic melanoma treated with IDO/PD-L1 targeting peptide vaccine and nivolumab.

Long-term follow-up of anti-PD-1 naïve patients with metastatic melanoma treated with IDO/PD-L1 targeting peptide vaccine and nivolumab.

Journal: Journal for immunotherapy of cancer

Published: May 03, 2023

First in man study: Bcl-Xl_42-CAF®09b vaccines in patients with locally advanced prostate cancer.

First in man study: Bcl-Xl_42-CAF®09b vaccines in patients with locally advanced prostate cancer.

Journal: Frontiers in immunology

Published: December 13, 2022

Arginase-1 targeting peptide vaccine in patients with metastatic solid tumors - A phase I trial.

Arginase-1 targeting peptide vaccine in patients with metastatic solid tumors - A phase I trial.

Journal: Frontiers in immunology

Published: August 19, 2022

Clinical advances and ongoing trials on mRNA vaccines for cancer treatment.

Clinical advances and ongoing trials on mRNA vaccines for cancer treatment.

Journal: The Lancet. Oncology

Published: April 19, 2022

Author Correction: A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma.

Author Correction: A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma.

Journal: Nature medicine

Published: March 09, 2022

Adoptive cell therapy with tumor-infiltrating lymphocytes supported by checkpoint inhibition across multiple solid cancer types.

Adoptive cell therapy with tumor-infiltrating lymphocytes supported by checkpoint inhibition across multiple solid cancer types.

Journal: Journal for immunotherapy of cancer

Published: September 13, 2021

A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma.

A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma.

Journal: Nature medicine

Published: February 19, 2021

CD19-Chimeric Antigen Receptor T Cells for Treatment of Chronic Lymphocytic Leukaemia and Acute Lymphoblastic Leukaemia.

CD19-Chimeric Antigen Receptor T Cells for Treatment of Chronic Lymphocytic Leukaemia and Acute Lymphoblastic Leukaemia.

Journal: Scandinavian journal of immunology

Published: May 12, 2015

Ectopic decidual reaction mimicking inguinal lymphoma on ultrasound.

Ectopic decidual reaction mimicking inguinal lymphoma on ultrasound.

Journal: Ultrasound (Leeds, England)

Published: August 01, 2014

Showing 1-12 of 12

Last Updated: 09/26/2026